Compare Expeditors International of Wshngtn Inc (EXPD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs TG Therapeutics Inc — how do they compare? Expeditors International of Wshngtn Inc trades at $177.4 (market cap $23.04B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Expeditors International of Wshngtn Inc is far larger — about 3× TG Therapeutics Inc's market cap, and Expeditors International of Wshngtn Inc pays a 0.91% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| EXPD | TGTX | |
|---|---|---|
Market Cap | $23.04B | $7.64B |
Sector | Industrials | Health |
52-Week High | $182.80 | $59.06 |
52-Week Low | $113.13 | $26.94 |
Enterprise Value | $22.57B | $7.84B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $184.47, up 3.06% with strong technical momentum and bullish moving averages. The company delivered three consecutive earnings beats, with Q2 2026 EPS surging 51% to $2.03, driven by airfreight demand and customs complexity. Revenue growth accelerated to $11.07B in 2025, though net margins compressed slightly to 7.32%. Analyst sentiment remains cautious with 63.6% hold ratings, but the stock trades above the consensus price target of $181.14.
Outlook remains positive with earnings momentum and expanding AOG services, but faces risks from ocean freight contraction and valuation concerns. The current P/E of 25.8x appears stretched relative to historical levels, while institutional ownership shows mixed signals with recent reductions. Near-term performance hinges on Q3 earnings delivery against $2.12 expectations.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
